Latest / The Buyer's Side with Fexingo: Procurement, Sourcing, and B2B Purchasing Decisions / How One Buyer Used Supplier-Led Innovation to Redesign a Core Component
Transcript
- Lucas: So there's this idea in procurement that keeps coming up in conferences and white papers — supplier-led innovation. Invite your key suppliers to redesign your products for you. It sounds great in theory. But most procurement teams I talk to say they've tried it once, got burned, and never went back. Luna: Burned how? Scope creep? IP disputes? Or just bad results? Lucas: All three. But I found a case where it actually worked — and the lessons are pretty specific. A mid-size medical device company — let's call them MedCore — was buying a pneumatic valve for one of their respiratory devices. This valve cost about $47 per unit. They bought 85,000 a year. So roughly $4 million annual spend on a single component. Luna: And they'd been buying the same spec for years, I'm guessing. Lucas: Exactly. The same print, same tolerances, same three approved suppliers — for over a decade. Then a new procurement director came in, looked at the total cost, and asked: 'Why does this thing cost $47?' Nobody in engineering could fully justify it. The design had been handed down from a predecessor. So instead of trying to reverse-engineer the cost internally, she tried something different. Luna: Let me guess — she invited suppliers to propose a better design. Lucas: Exactly. She called her three incumbent suppliers plus two new ones she'd identified through a trade show. She gave them a one-page document — not a spec, but a set of functional requirements. The valve needs to control airflow within these parameters, withstand these pressures, mate with this connector, and cost less than $40. Beyond that, you have design freedom. Luna: That's terrifying and liberating at the same time. How do you protect your IP if you give suppliers that much freedom? Lucas: That was the first thing she addressed. She had each supplier sign a joint development agreement before they saw any requirements. The agreement said any IP created specifically for this project would be jointly owned — but any background IP the supplier brought in remained theirs. And she capped the project at six weeks for a prototype. No open-ended R&D. Luna: Six weeks. That's tight for a medical device component. You've got validation testing, biocompatibility — Lucas: Right, but she wasn't asking for a production-ready part. She wanted a functional prototype and a cost model. Enough to evaluate whether the idea had legs. And she offered a $10,000 stipend to each participating supplier to cover their prototype costs. Not a huge amount, but it signaled she was serious and it leveled the playing field for smaller suppliers. Luna: So what happened? Did anyone come back with something interesting? Lucas: Three of the five submitted proposals. One was basically a minor tweak to the existing design — shave a few cents. Another proposed a completely different valve architecture using a ceramic piston instead of a metal one. But the winner — a small supplier they'd never worked with before — came back with something that blew everyone away. Luna: What was it? Lucas: They redesigned the valve using a high-performance polymer that eliminated the need for four separate internal parts. The original valve had twelve components. Their design had four. The part count reduction alone cut assembly time by 60 percent. And the polymer cost less than the metal it replaced. Their proposed unit price? $27.50. Luna: Forty-seven to twenty-seven fifty — that's a 41 percent cut. But wait, medical devices are regulated. You can't just swap materials without FDA re-approval. Lucas: That's the catch. The polymer wasn't fda approved for that application yet. So the buyer worked with the supplier to run the necessary biocompatibility testing. It took about nine months and cost around $80,000. But the annual savings were $2.3 million once the new design was approved. Payback period on the testing? Less than two weeks. Luna: That's a no-brainer. But I bet most procurement teams would have killed the idea at 'not fda approved'. Too risky. Lucas: And that's exactly the point. The buyer's willingness to invest a little to capture a lot — that's the mindset shift. She didn't treat the regulation as a hard stop. She treated it as a cost of entry. And she built a timeline that accounted for the approval cycle. Luna: So what's the lesson for a procurement team that wants to try supplier-led innovation but is scared of getting burned? Lucas: I think there are three guardrails. First, pick the right component. Don't try this on a commodity screw or a custom ASIC. Pick something where you don't have deep internal expertise and where the cost seems inflated relative to the complexity. That's where suppliers can add real value. Second, protect IP upfront — joint development agreement, clear ownership, no surprises. Third, give suppliers enough freedom to be creative but enough structure to keep them focused. Functional requirements, not detailed specs. A timebox. A small stipend. Luna: And be prepared to invest in testing and qualification. That's the hidden cost a lot of people miss. Lucas: Exactly. If your organization isn't willing to spend a little on validation, supplier-led innovation will always feel too risky. You'll end up with the same suppliers, the same designs, the same costs. Luna: You know, this episode — and honestly a lot of the conversations we have on this show — they've genuinely shifted how I think about procurement. It's not just negotiations and purchase orders. It's engineering, strategy, even product design. If you're listening and you've found value in these discussions, there's a small way to support the show. It's buy me a coffee dot com slash fexingo. That's buy me a coffee dot com slash fexingo. No pressure, just if the episodes have helped you in your work. Lucas: Yeah, and it genuinely makes a difference. It's what keeps the show ad-free and lets us dig into cases like this one. And honestly, the feedback we get from listeners who've tried these approaches — that's the real reward. So thank you to anyone who's contributed. Luna: Alright, back to the MedCore case. One thing I want to dig into — what happened to the incumbents? The suppliers who'd been selling that $47 valve for a decade. They must have been furious. Lucas: They were. One of them actually refused to participate in the innovation challenge. They said the existing design was 'optimized' and any change would introduce risk. That supplier lost the business entirely when the new design was approved. The other two incumbents did submit proposals, but their ideas were incremental — a few cents here, a minor material change there. They weren't willing to rethink the architecture. Luna: So the procurement director effectively disrupted her own supply base. That takes a certain kind of courage. Lucas: It does. And it's worth noting that she didn't just switch suppliers cold. She kept the winning supplier on a six-month trial with a limited volume commitment — 10,000 units — while the legacy supplier continued to supply the old design for service parts. So there was a transition period. But after the trial, the new design performed better, had fewer field failures, and cost less. The switch was permanent. Luna: Better performance too? Tell me about that. Lucas: The polymer had lower friction than the metal-on-metal interface in the original design. So the valve cycled more smoothly and lasted longer in durability testing. The mean time between failures went up by about 30 percent. That's huge for a respiratory device in a hospital setting. Fewer replacement parts, fewer service calls. Luna: So the total cost of ownership advantage was even bigger than the unit price suggested. Lucas: Much bigger. If you factor in the reduced failure rate, the total cost of ownership dropped by more than 50 percent. But the buyer's team didn't even model that upfront. They were so focused on the unit price that they almost missed the reliability benefit. It was only during the trial that they started tracking field failures and realized the new design was superior in every dimension. Luna: That's a good reminder. When you open up the design to suppliers, you might get benefits you didn't even ask for. The buyer didn't specify 'improve reliability' — she just said 'solve the airflow problem at lower cost.' The supplier optimized for cost and got reliability as a side effect. Lucas: Exactly. And that's the argument for giving suppliers a problem to solve rather than a specification to meet. Specifications are constraints. Problems are invitations. When you invite a supplier to solve your problem, you tap into their engineering creativity, their material science expertise, their manufacturing knowledge. All the things you're paying them for anyway. Luna: But this only works if you have a culture that tolerates a bit of uncertainty. Some procurement organizations are so risk-averse that any deviation from the existing spec is a non-starter. Lucas: Right. And that's a leadership issue. The procurement director at MedCore had a CFO who was willing to fund the $80,000 testing cost and the $30,000 in supplier stipends. That's a small bet for a potential $2.3 million annual return. But if your CFO treats procurement as a cost center rather than a value driver, you won't get that support. Luna: So the last piece of the puzzle is internal advocacy. You need to sell the idea upstream. Lucas: Exactly. And the way this buyer sold it was by framing it as a low-risk pilot. She didn't ask for a long-term commitment. She asked for $50,000 to run a six-week experiment with five suppliers. That's a small amount relative to the $4 million spend. Any CFO can say yes to that. Then once you have a winning prototype, the business case writes itself. Luna: That's a great playbook. Start small, limit the scope, prove the concept, then scale. It's almost like an innovation sprint for procurement. Lucas: Exactly. And I think that's the takeaway for episode 50. Supplier-led innovation isn't a theory. It's a practical tool — if you set the right guardrails, pick the right component, and invest a little to learn a lot. The MedCore team proved that a $50,000 experiment can unlock millions in savings and a better product. Luna: So for anyone listening, next time you're staring at a line item that feels overpriced and you don't know why — maybe don't try to cost-model it yourself. Maybe invite your suppliers to redesign it. Lucas: Yeah. And be ready for what they come back with. It might surprise you.